Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor

Completed · Phase 1/Phase 2

Conditions studied: Anemia, Aplastic

In brief

A single arm dose optimization study in which all patients are given a fixed dose of Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy is escalated or de-escalated dependent upon engraftment and toxicity.

Key facts

Study ID

NCT00144729

Run by

Fred Hutchinson Cancer Center

People needed

85

Starts

1993-05-01

Expected to finish

2007-07-01

Last updated by the study team

2008-04-30

Who can join

Age: any, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Life-threatening marrow failure of nonmalignant etiology;
• failure to respond to the best available immunosuppressive treatment;
• lack of a HLA-identical family member

You may not qualify if…

• Severe disease other than aplastic anemia that would severly limit the probability of survival during the graft procedure;
• HIV seropositive patients;
• clonal abnormalities or myelodysplastic syndrome;

Where it is running

• Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.